Polymyxin B Injection, Powder, Lyophilized, For Solution
Product Images NDC 25021-196

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Polymyxin B (NDC 25021-196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formulae (Pol0h 0000 01)

Chemical structure diagram showing the molecular composition of Polymyxin B1 and Polymyxin B2, highlighting amino acid sequences and chemical groups, including designation of the R group as CH3 or H respectively, with a sulfate component noted as .xH2SO4.*

FDA Label Image

Package Label – Principal Display Panel – Vial Label (Pol0h 0000 02)

Polymyxin B for Injection, USP 500,000 units per vial lyophilized powder label for hospital use only. Suitable for intramuscular, intravenous, and intrathecal administration. Contains Polymyxin B Sulfate equivalent to 500,000 units. Manufactured for Sagent Pharmaceuticals, Schaumburg, IL, made in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.